Eli Lilly and Company

Lilly and UNICEF accelerate non-communicable disease prevention and care to reach 30 million young people and caregivers in low- and middle-income countries.

Every child deserves a healthy start and future. Eli Lilly and Company is supportive of UNICEF’s efforts to make that a reality for millions of young people living with or at risk of non-communicable diseases (NCDs), including type 1 diabetes, sickle cell disease, asthma, and congenital and rheumatic heart disease.

Through Lilly’s support to UNICEF USA since 2022, UNICEF has reached nearly 16 million children in resource-limited settings in Bangladesh, Malawi, Nepal, the Philippines and Zimbabwe by strengthening health systems, training health workers and helping to integrate child-responsive NCD care within national health programs.

Separately, Lilly provided support to UNICEF USA in 2024 to strengthen primary health care capacity for promoting, preventing, and managing childhood NCDs in resource-limited settings in India.

Now in 2026, Lilly has committed to a new six-year collaboration, building on proven approaches to bring quality NCD prevention and care to 30 million young people and caregivers across 21 low- and middle-income countries, as well as to strengthen prevention, care and support for children living with overweight and obesity.

By supporting integrated, child-centred health systems, the collaboration is helping more children have a healthier start in life. This work advances Sustainable Development Goal 3 to ensure healthy lives and promote well-being for all and reflects a shared belief that when health systems are built with children in mind, entire communities benefit.

Read more about it.

UNICEF does not endorse any brand, company, product or service.

Last updated 14 May 2026